021-51111890
购物车（）
sales@molnova.cn
Quisinostat
CAS No. 875320-29-9
Quisinostat ( (JNJ-26481585) )
产品货号. M16360 CAS No. 875320-29-9
Quisinostat (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11.
纯度: >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥632 | 有现货 |
|
| 5MG | ￥1021 | 有现货 |
|
| 10MG | ￥1823 | 有现货 |
|
| 25MG | ￥2827 | 有现货 |
|
| 50MG | ￥3645 | 有现货 |
|
| 100MG | ￥5168 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Quisinostat
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Quisinostat (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11.
-
产品描述Quisinostat (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.
-
同义词(JNJ-26481585)
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC1; HDAC10; HDAC11; HDAC2; HDAC3; HDAC4; HDAC5; HDAC8
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number875320-29-9
-
分子量394.48
-
分子式C21H26N6O2
-
纯度>98%(HPLC)
-
溶解度DMSO:79 mg/mL (200.26 mM); Ethanol:<1 mg/mL (<1 mM); Water:<1 mg/mL (<1 mM)
-
SMILESO=C(C1=CN=C(N2CCC(CNCC3=CN(C)C4=C3C=CC=C4)CC2)N=C1)NO
-
化学全称N-hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Arts J, et al. Clin Cancer Res, 2009, 15(22), 6841-685
